Navigation Links
Hanger Announces 2013 Year-To-Date Acquisitions Totaling $10 Million Of Annualized Net Revenue

AUSTIN, Texas, Aug. 19, 2013 /PRNewswire/ -- Hanger, Inc. (NYSE: HGR) today announced that in 2013 year-to-date it has completed the acquisition of four patient care companies comprised of nine clinics in six states with annualized revenue of approximately $10 million. The acquisitions are East Coast Orthotics, Inc.; Nascott, Inc.; Keller's Limb & Brace, Inc. dba Snell's of Jackson; and Development & Research, Inc., dba San Juan P&O.

"We are pleased to welcome these great companies and their over 60 dedicated clinicians and staff to the Hanger team," commented Vinit K. Asar, President and CEO of Hanger. "We are half way to meeting our 2013 goal to acquire annualized sales of approximately $20 million. Our pipeline of transactions remains healthy."

About Hanger, Inc. – Built on the legacy of James Edward Hanger, the first amputee of the American Civil War, Hanger, Inc. (NYSE: HGR) delivers orthotic and prosthetic (O&P) patient care, and distributes O&P products and rehabilitative solutions to the broader market.  Hanger's Patient Care segment is the largest owner and operator of O&P patient care clinics with in excess of 730 locations nationwide.  Through its Products & Services segment, Hanger distributes branded and private label O&P devices, products and components, and provides rehabilitative solutions.  Steeped in over 150 years of clinical excellence and innovation, Hanger's vision is to be the partner of choice for products and services that enhance human physical capability.  For more information on Hanger, visit and follow us at,, and  

This document contains forward-looking statements relating to the Company's results of operations.  The United States Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements.  Statements relating to future results of operations in this document reflect the current views of management.  However, various risks, uncertainties and contingencies could cause actual results or performance to differ materially from those expressed in, or implied by, these statements, including the Company's ability to enter into and derive benefits from managed care contracts, the demand for the Company's orthotic and prosthetic services and products, the impact of reviews, audits and investigations conducted from time to time by governmental agencies, and the other factors identified in Item 1A, "Risk Factors" in the Company's periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934.  The Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Hanger, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hanger Reports Second Quarter 2013 Results
2. Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities
3. Hanger elects Thomas P. Cooper, M.D. Chairman of the Board
4. Change Healthcares Clayton Nicholas to Speak on "Game Mechanics and Other Game Changers in Benefits Education" at IHC Forum East
5. Hanger Reports First Quarter 2013 Results
6. Hanger, Inc. Announces First Quarter 2013 Earnings Release And Conference Call
7. Hanger Files Form 10-K for Year Ended December 31, 2012
8. Hanger Reports $0.62 Diluted EPS for the Fourth Quarter 2012
9. Hanger, Inc. Has Record Year In O&P Acquisitions:
10. Hanger Reports Earnings of $0.50 Per Diluted Share for the Third Quarter 2012
11. Hanger, Inc. Announces 2012 Year To Date Acquisitions Totaling $35.6 Million Of Annual Net Revenue
Post Your Comments:
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
Breaking Medicine News(10 mins):